We have updated our Privacy Policy. Please review our Privacy Policy. This website uses cookies. By using our website without changing your cookie settings, you agree to our use of cookies as described in our Privacy Policy.

ONCE-MONTHLY VIVITROL ALONG WITH COUNSELING MAY GIVE YOU A PATH FORWARD IN YOUR OPIOID DEPENDENCE RECOVERY JOURNEY1

Opioid dependence can be challenging, but you are not alone. After opioid detoxification, VIVITROL and counseling may help prevent relapse to opioid dependence.1,2

VIVITROL and counseling have been proven to prevent relapse to opioid dependence after opioid detox1,3*

In a 6-month, double-blind, placebo-controlled randomized clinical study of opioid dependent patients following opioid detoxification, complete abstinence (opioid-free at all weekly visits) was maintained in 36% of patients treated with VIVITROL and counseling compared to 23% of patients treated with placebo and counseling from Week 5 to Week 24.

*Opioid-free was defined as a negative urine drug test for opioids and no self-reported opioid use. Data were not collected during Weeks 1-4 of the clinical trial to allow for stabilization of abstinence.

Patient self-reported opioid craving3,4

In the same study, craving described as a "need for opioids" and measured on a visual scale from 0-100, with 0 being "none" and 100 being "very much so," was reported by patients every week.

Patients treated with VIVITROL and counseling had a -10.1 change in craving score (55% lower than the average score at start of treatment), while patients treated with placebo and counseling had a +0.7 change in craving score (3% higher than the average score at start of treatment).

Individuals used a visual analog scale (VAS) to self-assess their craving levels throughout the trial.

VIVITROL is a once-monthly injection1

Your recovery journey is worth fighting for. Ask your healthcare provider if once-monthly VIVITROL may be right for you.


“No matter how much fear I had, I was willing to go through it... I figured once I got on a road that could give me a foundation, I could keep going.”

Christina on her personal recovery journey

Patient stories reflect personal experiences.
Individual experiences may vary.
See Christina's story

NEED HELP PREPARING FOR TREATMENT?

These tips may help you prepare for your VIVITROL injection.

Learn more

VIVITROL is not right for everyone. There are significant risks from VIVITROL treatment, including risk of opioid overdose, severe reaction at the injection site, sudden opioid withdrawal, liver damage, or hepatitis.

Talk to your healthcare provider about naloxone, a medicine that is available to patients for the emergency treatment of an opioid overdose.

Call 911 or get emergency medical help right away in all cases of known or suspected opioid overdose, even if naloxone is administered.

If you are being treated for alcohol dependence but also use or are addicted to opioid-containing medicines or opioid street drugs, it is important that you tell your healthcare provider before starting VIVITROL to avoid having sudden opioid withdrawal symptoms when you start VIVITROL treatment.

See Important Safety Information.

See Prescribing Information and Medication Guide.


References: 1. VIVITROL [prescribing information]. Waltham, MA: Alkermes, Inc; rev. March 2021. 2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. text revision. Washington, DC: American Psychiatric Association; 2000. 3. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-1513. 4. Data on file. Alkermes, Inc. Waltham, MA.

References: 1. VIVITROL [prescribing information]. Waltham, MA: Alkermes, Inc; rev. March 2021. 2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. text revision. Washington, DC: American Psychiatric Association; 2000. 3. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-1513. 4. Data on file. Alkermes, Inc. Waltham, MA.